Pierre Karam

Mr. Pierre Karam

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2023 in Toxins
Verified
Journal Article
Open access
PDF file
DBDjamel Bensmail
Djamel Bensmail
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
JLJean-Yves Loze
Jean-Yves Loze
JLJonathan Levy
Jonathan Levy
There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d’Information, PMSI) covering the entire French population. Among 105,206 patients coded with MS, we identified those who received ≥1 BoNT-A injection, administered within striated muscle for MS-related spasticity and/or within the detrusor smooth muscle for neurogenic detrusor overactivity (NDO). A total of 8427 patients (8.0%) received BoNT-A injections for spasticity, 52.9% of whom received ≥3 BoNT-A injections with 61.9% of the repeated injections administered every 3 to 6 months. A total of 2912 patients (2.8%) received BoNT-A injections for NDO, with a mean of 4.7 injections per patient. Most repeated BoNT-A injections within the detrusor smooth muscle (60.0%) were administered every 5 to 8 months. There were 585 patients (0.6%) who received both BoNT-A injections within striated muscle and the detrusor smooth muscle. Overall, our study highlights a broad range of BoNT-A treatment practices between 2014 and 2020 in patients with MS.

1 October 2024 in Toxins
Verified
Journal Article
Open access
PDF file
ARAlain Ruffion
Alain Ruffion
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
PDPierre Denys
Pierre Denys
In recent decades, intradetrusor injections of botulinum toxin A (BoNT-A) have been widely applied to treat incontinence in both idiopathic overactive bladder (iOAB) and neurogenic detrusor overactivity incontinence (NDOI). This analysis, based on the French National Hospital Discharge Database (PMSI), aims to describe real-world trends in intradetrusor BoNT-A use between 2014 and 2022. Among 32,864 patients who received at least one intradetrusor BoNT-A injection, 18,320 (55.7%) had conditions coded under iOAB, 13,376 (40.7%) under NDOI, and 1168 (3.6%) under other indications. The overall mean interval between two intradetrusor BoNT-A injections was 9.7 months, ranging from 8.7 months in patients with multiple sclerosis (MS) to 11.5 months in patients with cerebral pathologies. The median number of injections was two (quartile 1–quartile 3, 1–4) in patients with spina bifida, whereas it was five (2–10) in those with MS. Only 31% of patients with iOAB received more than two intradetrusor BoNT-A injections. Regardless of its indication, BoNT-A was well tolerated. Adverse events occurring during or requiring hospitalization included infections (3.8%), hematuria (0.53%), and bleeding episodes necessitating transfusions (0.11%), all recorded within the initial month following BoNT-A injection. Our analysis of the PMSI database highlights a broad spectrum of intradetrusor BoNT-A injection practices.

11 December 2025 in Neuroepidemiology
Verified
Journal Article
Open access
EOEtienne Ojardias
Etienne Ojardias
JLJonathan Levy
Jonathan Levy
LZLorène Zerah
Lorène Zerah
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
RHRebecca Haddad
Rebecca Haddad
Introduction: While botulinum toxin type A (BoNT-A) is effective for poststroke spasticity, its accessibility in older adults remains unclear. We aimed to examine the association between BoNT-A use and age among stroke survivors. Methods: This nationwide, population-based, retrospective cohort study analyzed data from the French National Hospital Discharge Database. Stroke survivors admitted between 2014 and 2016 were followed until 2020. BoNT-A use was assessed across different age groups (18–64, 65–74, 75–84, ≥85 years). Multivariable logistic regression was performed to examine the association between BoNT-A use and age, adjusting for potential confounders, including sex, comorbidities, stroke unit hospitalization, and rehabilitation. Results: BoNT-A use was reported in 1,757 (2.88%), 862 (0.99%), and 183 (0.22%) of 60,928, 86,917, and 82,725 stroke survivors aged 65–74, 75–84, and ≥85 years, respectively. These rates were significantly lower than BoNT-A use in those aged <65 years (5.13%) (p < 0.001). After adjustment, the inverse relationship between age and BoNT-A use was maintained, demonstrating an age-dependent association in the 65–74, 75–84, and ≥85 age groups vs. 18–64 years. Odds ratios (ORs) (95% confidence intervals [CIs]) were 0.49 (0.47–0.53), 0.18 (0.17–0.19), and 0.05 (0.04–0.06), respectively. Stroke unit stays (OR, 1.33; 95% CI, 1.26–1.41) and neurological rehabilitation unit stays (OR, 16.69; 95% CI, 15.59–17.87) were significantly associated with a higher probability of receiving BoNT-A. Conclusions: BoNT-A use is notably low in older stroke survivors, highlighting the need to enhance equitable access to BoNT-A injections for this population.

4 December 2025 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
SAStéphane Auvin
Stéphane Auvin
MHMarc-Antoine Hamandjian
Marc-Antoine Hamandjian
PKPierre Karam
Pierre Karam
CHCélia Hoebeke
Célia Hoebeke
Neuronal ceroid lipofuscinoses (NCLs) are rare, progressive lysosomal neurodegenerative disorders. Among late-infantile onset forms (after 18 months of age), type 2 (CLN2 disease) is the most frequent. This study assessed the incidence and disease burden at diagnosis of CLN2 disease in France. This was a nationwide, population-based, retrospective study including all patients identified with CLN2 disease in the French Hospital Discharge Database (Programme de Médicalisation des Systèmes d'Information, PMSI) from January 2015 to December 2023. After a 2-year washout period to exclude prevalent patients, 51 children were considered to have been diagnosed with CLN2 disease over 7 years (2017-2023). Based on national birth statistics, this corresponds to an incidence of 0.99 cases of CLN2 disease per 100,000 live births. Median age at diagnosis was 5 years (interquartile range, 3-8), with a mean diagnostic delay of 19.1 ± 19.8 months from the first coded symptoms. Epilepsy (90.2 %) and intellectual disability (86.3 %) were the most frequently coded comorbidities. Of the 51 children, 84.3 % were hospitalized via emergency care, and 45.1 % required intensive care. Overall, 13 deaths (25.5 %) were reported, with median age at death of 9 years. This is the first nationwide epidemiological assessment of CLN2 disease in France. The results demonstrate substantial diagnostic delays and disease burden, underscoring the need for earlier diagnosis and referral to expert centers to optimize care and offer genetic counseling to parents before conceiving subsequent offspring.

24 May 2026 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
MSMarion Simonetta‐Moreau
Marion Simonetta‐Moreau
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
BDBertrand Degos
Bertrand Degos
Background: Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective: This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023, using the French National Hospital Discharge Database ( Programme de Médicalisation des Systèmes d'Information , PMSI). Methods: Patients were classified into four categories (dystonia, tremor, myoclonus, and other abnormal movements), based on International Classification of Diseases, 10th Revision (ICD‐10). Annual changes in the number of BoNT‐A injections and treated patients were analyzed. Treatment adherence and reinjection intervals were also evaluated. Results: A total of 51,861 patients received BoNT‐A therapy. Dystonia was the predominant indication (44,913; 86.6%). Tremor accounted for 3690 patients (7.1%), other abnormal movements for 2423 (4.7%), and myoclonus for 835 (1.6%). Between 2015 and 2023, BoNT‐A injections increased from 49,829 to 53,828 (+8.0%) and treated patients from 20,023 to 21,489 (+7.3%). While dystonia showed minimal growth in patient numbers (+0.6%), tremor and myoclonus increased substantially (+132.1% and +179.7%, respectively). Repeat BoNT‐A injections were highest in dystonia, with 71.8% of patients receiving ≥3 injections and 57.9% receiving ≥5 injections in total. Median reinjection intervals ranged from 112 days in dystonia to 133 days in myoclonus. Conclusions: Dystonia remains the leading indication for BoNT‐A in France, with high treatment adherence. The marked growth in tremor and myoclonus underscores the expanding therapeutic role and diversification of BoNT‐A use across hyperkinetic movement disorders.